Profile - To The Moon

GolDBeaR

Posts · 33Posts · 33
Following · 0Following · 0
Followers · 0Followers · 0

- GolDBeaRGolDBeaR
  ·02-06
  $Palantir Technologies Inc.(PLTR)$
  152 Comment
  Like
  Share
  Report
- GolDBeaRGolDBeaR
  ·2022-08-03
  $Moderna, Inc.(MRNA)$keep up
  250 Comment
  Like
  Share
  Report
- GolDBeaRGolDBeaR
  ·2022-07-14
  Come on
  EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%
  EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.
  EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%
  156 Comment
  1
  Share
  Report
- GolDBeaRGolDBeaR
  ·2022-07-14
  $Palantir Technologies Inc.(PLTR)$ waiting for
  126 Comment
  Like
  Share
  Report
- GolDBeaRGolDBeaR
  ·2022-01-04
  Covid last forever
  Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents
  A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with
  Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents
  136 Comment
  Like
  Share
  Report
- GolDBeaRGolDBeaR
  ·2022-01-04
  Superb
  Tesla Adds $144 Billion to Market Value After Record Deliveries
  Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worl
  Tesla Adds $144 Billion to Market Value After Record Deliveries
  391 Comment
  1
  Share
  Report
- GolDBeaRGolDBeaR
  ·2021-12-31
  Superb
  143 Comment
  Like
  Share
  Report
- GolDBeaRGolDBeaR
  ·2021-12-27
  Sounds sweet
  Sorry, this post has been deleted
  97 Comment
  3
  Share
  Report
- GolDBeaRGolDBeaR
  ·2021-12-27
  Up up
  @4ZOEYS：
  $Tiger Brokers(TIGR)$Moved a little too fast,
  $Tiger Brokers(TIGR)$Moved a little too fast,
  261 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4095642275585470","uuid":"4095642275585470","gmtCreate":1635384032915,"gmtModify":1641713927280,"name":"GolDBeaR","pinyin":"goldbear","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":12,"tweetSize":33,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":271133400080600,"gmtCreate":1707232627986,"gmtModify":1707232631259,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","text":"$Palantir Technologies Inc.(PLTR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271133400080600","isVote":1,"tweetType":1,"viewCount":152,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9906656398,"gmtCreate":1659538651317,"gmtModify":1705981390546,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","listText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","text":"$Moderna, Inc.(MRNA)$keep up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906656398","isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076167786,"gmtCreate":1657812205945,"gmtModify":1676536065700,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Come on","listText":"Come on","text":"Come on","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076167786","repostId":"1178687942","repostType":2,"repost":{"id":"1178687942","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1657807271,"share":"https://ttm.financial/m/news/1178687942?lang=&edition=fundamental","pubTime":"2022-07-14 22:01","market":"us","language":"en","title":"EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178687942","media":"Tiger Newspress","summary":"EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.","content":"<html><head></head><body><p>EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.<img src=\"https://static.tigerbbs.com/e4346325d5520a81cba5e77d0588bce5\" tg-width=\"265\" tg-height=\"357\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-07-14 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.<img src=\"https://static.tigerbbs.com/e4346325d5520a81cba5e77d0588bce5\" tg-width=\"265\" tg-height=\"357\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178687942","content_text":"EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076165077,"gmtCreate":1657811900999,"gmtModify":1676536065661,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$ waiting for","images":[{"img":"https://community-static.tradeup.com/news/d673b361e8e98bbbaccd32998ce2b23b","width":"1344","height":"2389"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076165077","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9001793279,"gmtCreate":1641311984824,"gmtModify":1676533596753,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Covid last forever","listText":"Covid last forever","text":"Covid last forever","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001793279","repostId":"1143463942","repostType":2,"repost":{"id":"1143463942","pubTimestamp":1640831989,"share":"https://ttm.financial/m/news/1143463942?lang=&edition=fundamental","pubTime":"2021-12-30 10:39","market":"us","language":"en","title":"Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=1143463942","media":"WSJ","summary":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with ","content":"<html><head></head><body><p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.</p><p>The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.</p><p>At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?</p><p>Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.</p><p>“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/391659260599217c12076cea6c888697\" tg-width=\"1007\" tg-height=\"668\" width=\"100%\" height=\"auto\"/><span>The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNAL</span></p><p>The emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.</p><p>Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.</p><p>They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly&amp; Co.’s cancer drug Alimta, based on research by a university professor.</p><p>Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.</p><p>Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/125cd1b51bc213c732cc20b023d56df3\" tg-width=\"1352\" tg-height=\"734\" width=\"100%\" height=\"auto\"/><span>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESS</span></p><p>The market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.</p><p>Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.</p><p>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.</p><p>One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.</p><p>The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/841b456b86547fecd4464e1358e26c20\" tg-width=\"1298\" tg-height=\"684\" width=\"100%\" height=\"auto\"/><span>A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNAL</span></p><p>Moderna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.</p><p>Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.</p><p>Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.</p><p>This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.</p><p>The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3380b351f910af68ef191b100997c93\" tg-width=\"957\" tg-height=\"615\" width=\"100%\" height=\"auto\"/><span>Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWS</span></p><p>A second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.</p><p>Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.</p><p>As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.</p><p>Moderna didn’t respond to a request for comment regarding the patent.</p><p>Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.</p><p>In October 2020, a small San Diego company, Allele Biotechnology &amp; Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.</p><p>Pfizer and BioNTech dispute the claim, and the litigation is pending.</p><p>Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.</p><p>Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.</p><p>A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.</p><p>More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.</p><p>That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.</p><p>A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Invented Covid-19 Vaccines? Drugmakers Battle Over Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented ...</p>\n\n<a href=\"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143463942","content_text":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNALThe emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly& Co.’s cancer drug Alimta, based on research by a university professor.Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESSThe market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNALModerna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWSA second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.Moderna didn’t respond to a request for comment regarding the patent.Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.In October 2020, a small San Diego company, Allele Biotechnology & Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.Pfizer and BioNTech dispute the claim, and the litigation is pending.Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.","news_type":1},"isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001559759,"gmtCreate":1641283730205,"gmtModify":1676533592864,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001559759","repostId":"1102940638","repostType":2,"repost":{"id":"1102940638","pubTimestamp":1641254417,"share":"https://ttm.financial/m/news/1102940638?lang=&edition=fundamental","pubTime":"2022-01-04 08:00","market":"us","language":"en","title":"Tesla Adds $144 Billion to Market Value After Record Deliveries","url":"https://stock-news.laohu8.com/highlight/detail?id=1102940638","media":"Bloomberg","summary":"Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worl","content":"<html><head></head><body><ul><li>Monday’s 14% gain is stock’s best performance to start a year</li><li>Company delivered 308,600 vehicles worldwide in fourth quarter</li></ul><p>Tesla Inc. is off to a strong start to the new year after the electric-car maker smashed its quarterly record for deliveries in what one analyst called a “trophy-case” performance.</p><p>The company’s shares jumped 14% in New York, their biggest gain since March and best start to a year since Tesla went public more than a decade ago. The $144 billion in market value that Tesla added on Monday is the equivalent of an entire Honeywell International Inc. or Starbucks Corp. It’s also more than the value of almost 90% of the companies in the S&amp;P 500 Index.</p><p><img src=\"https://static.tigerbbs.com/b98c9fe43c27a22e44f07c72304c2671\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"/></p><p>Worldwide deliveries totaled 308,600 vehicles in the fourth quarter, well ahead of the average analyst estimate of roughly 263,000 vehicles, and topping the company’s previous record of 241,300 from the prior quarter. Annual handovers surged to more than 936,000 in 2021, up 87% from the previous year’s level, Austin, Texas-based Tesla said Sunday.</p><p>“This is a trophy-case quarter for Tesla as the company blew away even bull-case expectations,” Daniel Ives, an analyst at Wedbush Securities, said in an email. He called it a “jaw-dropper performance” for the end of the year that gives “massive tailwinds” heading into 2022.</p><p>The record quarter underscores the “green tidal wave taking hold” for Tesla and Chief Executive Officer Elon Musk, Ives said in a note to clients. The results also point to robust demand in China and Tesla’s skill at navigating the global semiconductor shortage, he said.</p><p>Musk, who has pledged delivery growth despite the “supply-chain nightmare” of 2021, praised his crew on Twitter.</p><p><img src=\"https://static.tigerbbs.com/ee8ecf3d5f76e1a511459de02365693c\" tg-width=\"830\" tg-height=\"496\" referrerpolicy=\"no-referrer\"/></p><p>Quarterly deliveries are one of the most closely watched indicators for Tesla. They underpin its financial results and are widely seen as a barometer of consumer demand for electric vehicles as a whole because the company has led the charge for battery-powered cars.</p><p>Tesla has said repeatedly it expects 50% annual increases in deliveries over a multiyear period. The seventh consecutive quarterly gain comes amid a global semiconductor slump that has crimped production at most other automakers and kept sales in check despite rising demand.</p><p>“Tesla continues to execute well, posting deliveries and production above consensus expectations,” Cowen analyst Jeffrey Osborne said. “As the competition heats up from incumbent OEMs and new entrants alike, we see 2022 becoming a critical year for Tesla.”</p><p>The EV market leader’s stock soared almost 50% in 2021 to give it a market valuation exceeding $1 trillion -- one of only a handful of U.S.-based public companies to achieve that status.</p><p>The shares reached a record high in early November before plunging after Musk began unloading 10% of his stake.</p><p><a href=\"https://ttm.financial/NW/1195533166\" target=\"_blank\"><b>Elon Musk’s Fortune Climbs $30 Billion on Tesla’s Record Quarter for Deliveries</b></a><b></b></p><p>Elon Musk started 2022 with a bang.</p><p><img src=\"https://static.tigerbbs.com/9bb18462e67b743b94632bf0093ff927\" tg-width=\"1000\" tg-height=\"667\" referrerpolicy=\"no-referrer\"/></p><p>Tesla Inc. reported it had smashed its previous record for vehicle deliveries, spurring a rally in the electric car-maker’s shares and creating one of the biggest one-day jumps in wealth.</p><p>Musk’s fortune jumped by $33.8 billion on Monday to $304.2 billion, according to the Bloomberg Billionaires Index. Jeff Bezos, second on the list, has a $196 billion fortune.</p><p>Tesla’s shares rose 13.5% to $1,199.78 on Monday after fourth-quarter results handily exceeded analysts’ estimates for auto deliveries.</p><p>The company’s market valuation jumped back above $1 trillion last month after a dip in November and early December.</p><p>Musk, who owns about 18% of Tesla, helped trigger the slide when he said he would reduce his stake in the company by 10%. He’ssoldmore than $10 billion worth of shares since November, part of a plan to generate cash to pay tax obligations.</p><p>Musk’s net worth, which also includes his stake in rocket manufacterer SpaceX, reached a high of $340 billion last year, surpassing the peak inflation-adjusted net worth of John D. Rockefeller and briefly making him the richest person in modern history.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Adds $144 Billion to Market Value After Record Deliveries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Adds $144 Billion to Market Value After Record Deliveries\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-04 08:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worldwide in fourth quarterTesla Inc. is off to a strong start to the new year after the electric-car ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102940638","content_text":"Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worldwide in fourth quarterTesla Inc. is off to a strong start to the new year after the electric-car maker smashed its quarterly record for deliveries in what one analyst called a “trophy-case” performance.The company’s shares jumped 14% in New York, their biggest gain since March and best start to a year since Tesla went public more than a decade ago. The $144 billion in market value that Tesla added on Monday is the equivalent of an entire Honeywell International Inc. or Starbucks Corp. It’s also more than the value of almost 90% of the companies in the S&P 500 Index.Worldwide deliveries totaled 308,600 vehicles in the fourth quarter, well ahead of the average analyst estimate of roughly 263,000 vehicles, and topping the company’s previous record of 241,300 from the prior quarter. Annual handovers surged to more than 936,000 in 2021, up 87% from the previous year’s level, Austin, Texas-based Tesla said Sunday.“This is a trophy-case quarter for Tesla as the company blew away even bull-case expectations,” Daniel Ives, an analyst at Wedbush Securities, said in an email. He called it a “jaw-dropper performance” for the end of the year that gives “massive tailwinds” heading into 2022.The record quarter underscores the “green tidal wave taking hold” for Tesla and Chief Executive Officer Elon Musk, Ives said in a note to clients. The results also point to robust demand in China and Tesla’s skill at navigating the global semiconductor shortage, he said.Musk, who has pledged delivery growth despite the “supply-chain nightmare” of 2021, praised his crew on Twitter.Quarterly deliveries are one of the most closely watched indicators for Tesla. They underpin its financial results and are widely seen as a barometer of consumer demand for electric vehicles as a whole because the company has led the charge for battery-powered cars.Tesla has said repeatedly it expects 50% annual increases in deliveries over a multiyear period. The seventh consecutive quarterly gain comes amid a global semiconductor slump that has crimped production at most other automakers and kept sales in check despite rising demand.“Tesla continues to execute well, posting deliveries and production above consensus expectations,” Cowen analyst Jeffrey Osborne said. “As the competition heats up from incumbent OEMs and new entrants alike, we see 2022 becoming a critical year for Tesla.”The EV market leader’s stock soared almost 50% in 2021 to give it a market valuation exceeding $1 trillion -- one of only a handful of U.S.-based public companies to achieve that status.The shares reached a record high in early November before plunging after Musk began unloading 10% of his stake.Elon Musk’s Fortune Climbs $30 Billion on Tesla’s Record Quarter for DeliveriesElon Musk started 2022 with a bang.Tesla Inc. reported it had smashed its previous record for vehicle deliveries, spurring a rally in the electric car-maker’s shares and creating one of the biggest one-day jumps in wealth.Musk’s fortune jumped by $33.8 billion on Monday to $304.2 billion, according to the Bloomberg Billionaires Index. Jeff Bezos, second on the list, has a $196 billion fortune.Tesla’s shares rose 13.5% to $1,199.78 on Monday after fourth-quarter results handily exceeded analysts’ estimates for auto deliveries.The company’s market valuation jumped back above $1 trillion last month after a dip in November and early December.Musk, who owns about 18% of Tesla, helped trigger the slide when he said he would reduce his stake in the company by 10%. He’ssoldmore than $10 billion worth of shares since November, part of a plan to generate cash to pay tax obligations.Musk’s net worth, which also includes his stake in rocket manufacterer SpaceX, reached a high of $340 billion last year, surpassing the peak inflation-adjusted net worth of John D. Rockefeller and briefly making him the richest person in modern history.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003327935,"gmtCreate":1640884649383,"gmtModify":1676533551118,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[{"img":"https://static.itradeup.com/news/04bd5d6fab6a75ca6b03b059bbdf6566","width":"1344","height":"2139"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003327935","isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9009825780,"gmtCreate":1640617239238,"gmtModify":1676533529571,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Sounds sweet","listText":"Sounds sweet","text":"Sounds sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009825780","repostId":"1114062676","repostType":2,"isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009823704,"gmtCreate":1640616470570,"gmtModify":1676533529449,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009823704","repostId":"9009820967","repostType":1,"repost":{"id":9009820967,"gmtCreate":1640616177720,"gmtModify":1676533529377,"author":{"id":"3576159031156193","authorId":"3576159031156193","name":"4ZOEYS","avatar":"https://static.tigerbbs.com/485a6405c364ce85c22e81b2913d390f","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3576159031156193","authorIdStr":"3576159031156193"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","text":"$Tiger Brokers(TIGR)$Moved a little too fast,","images":[{"img":"https://static.itradeup.com/news/c56f3695dae52d48a6c8a24c1ca8e88d","width":"1125","height":"3766"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009820967","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}